GH Research Announces Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001 in Treatment-Resistant Depression
· Issued by Gh Research Plc
- Primary endpoint met in Phase 2 part of clinical trial for GH001 in TRD
- 7 of 8 patients (87.5%) were in remission (MADRS ≤10) at day 7 after dosing (p
